Zacks: Analysts Expect Tandem Diabetes Care Inc (TNDM) to Post -$0.22 Earnings Per Share
Equities analysts forecast that Tandem Diabetes Care Inc (NASDAQ:TNDM) will report earnings per share (EPS) of ($0.22) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Tandem Diabetes Care’s earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.24). Tandem Diabetes Care posted earnings of ($1.23) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 82.1%. The firm is scheduled to announce its next earnings report after the market closes on Tuesday, February 26th.
According to Zacks, analysts expect that Tandem Diabetes Care will report full-year earnings of ($3.22) per share for the current fiscal year, with EPS estimates ranging from ($3.83) to ($3.04). For the next year, analysts anticipate that the firm will post earnings of ($0.77) per share, with EPS estimates ranging from ($1.18) to ($0.64). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that that provide coverage for Tandem Diabetes Care.
Several analysts recently issued reports on TNDM shares. Oppenheimer set a $57.00 price target on Tandem Diabetes Care and gave the company a “buy” rating in a report on Friday, November 2nd. BidaskClub upgraded Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 12th. Lake Street Capital set a $60.00 target price on Tandem Diabetes Care and gave the company a “buy” rating in a research note on Monday, October 15th. Robert W. Baird upgraded Tandem Diabetes Care from a “neutral” rating to an “outperform” rating and set a $46.00 target price for the company in a research note on Wednesday, November 21st. Finally, UBS Group started coverage on Tandem Diabetes Care in a research note on Tuesday, November 27th. They set a “neutral” rating and a $36.00 target price for the company. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $44.75.
Hedge funds and other institutional investors have recently modified their holdings of the business. PNC Financial Services Group Inc. bought a new position in Tandem Diabetes Care in the fourth quarter worth about $44,000. IFP Advisors Inc lifted its holdings in Tandem Diabetes Care by 78.4% in the fourth quarter. IFP Advisors Inc now owns 1,757 shares of the medical device company’s stock worth $66,000 after acquiring an additional 772 shares during the last quarter. US Bancorp DE lifted its holdings in Tandem Diabetes Care by 397.8% in the third quarter. US Bancorp DE now owns 2,489 shares of the medical device company’s stock worth $107,000 after acquiring an additional 1,989 shares during the last quarter. Tower Research Capital LLC TRC bought a new position in Tandem Diabetes Care in the third quarter worth about $109,000. Finally, Meeder Asset Management Inc. lifted its holdings in Tandem Diabetes Care by 1,921.6% in the third quarter. Meeder Asset Management Inc. now owns 2,709 shares of the medical device company’s stock worth $116,000 after acquiring an additional 2,575 shares during the last quarter. 72.17% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ TNDM traded up $1.37 during trading hours on Wednesday, hitting $43.66. The company had a trading volume of 30,514 shares, compared to its average volume of 1,003,399. Tandem Diabetes Care has a fifty-two week low of $2.14 and a fifty-two week high of $52.55. The company has a market cap of $2.50 billion, a P/E ratio of -3.40 and a beta of 0.49.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Read More: Why does a company issue an IPO?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.